M&T Bank Corp Purchases 143 Shares of DaVita Inc. (NYSE:DVA)

M&T Bank Corp raised its position in DaVita Inc. (NYSE:DVA) by 4.2% during the third quarter, Holdings Channel reports. The fund owned 3,534 shares of the company’s stock after acquiring an additional 143 shares during the period. M&T Bank Corp’s holdings in DaVita were worth $579,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of DVA. Nomura Asset Management Co. Ltd. grew its position in DaVita by 0.4% during the third quarter. Nomura Asset Management Co. Ltd. now owns 28,790 shares of the company’s stock valued at $4,720,000 after buying an additional 117 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of DaVita in the 3rd quarter worth $1,225,000. MML Investors Services LLC raised its holdings in DaVita by 1.3% in the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock worth $869,000 after purchasing an additional 68 shares during the period. XTX Topco Ltd lifted its position in DaVita by 22.5% during the third quarter. XTX Topco Ltd now owns 5,815 shares of the company’s stock valued at $953,000 after purchasing an additional 1,069 shares in the last quarter. Finally, National Bank of Canada FI grew its holdings in DaVita by 14.6% during the third quarter. National Bank of Canada FI now owns 38,232 shares of the company’s stock valued at $6,267,000 after purchasing an additional 4,876 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Down 2.0 %

Shares of DVA opened at $147.53 on Wednesday. The business’s 50 day moving average is $157.67 and its 200 day moving average is $150.89. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 12-month low of $103.40 and a 12-month high of $169.51. The company has a market capitalization of $12.10 billion, a PE ratio of 15.91, a price-to-earnings-growth ratio of 0.86 and a beta of 0.90.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted $2.85 EPS. Research analysts expect that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on DVA shares. Truist Financial raised their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.